Drug major Cipla on Friday posted 73 per cent rise in consolidated net profit at Rs 412 crore for the fourth quarter ended March 31, 2021 on the back of robust sales across markets. The Mumbai-based firm had reported a net profit of Rs 238 crore in January-March 2019-20.

Reacting to the developments, Shares of Cipla gained over 0.60 percent on Friday in NSE. The stock finally quoting at Rs.904 per unit as compared to the previous close of Rs. 898.60.

The company's board recommended a final dividend of Rs 5 per share (face value Rs 2 each) for 2020-21

Cipla’s Total revenue from operations rose to Rs 4,606 crore as compared with Rs 4,376 crore in the same period of 2019-20, Cipla said in a regulatory filing. For the entire 2020-21 fiscal year, Cipla reported a consolidated net profit of Rs 2,389 crore as against Rs 1,500 crore in 2019-20. Total revenue from operations in the last fiscal year rose to Rs 19,160 crore as against Rs 17,132 crore in 2019-20.

Commenting on the COVID situation, Cipla MD and Global CEO Umang Vohra said the company stands firmly with the nation as it continues the fight against a massive second wave of the pandemic. ''We are privileged to be a part of an industry which is at the centre of this fight. We have been relentless in our efforts to ensure the continuity of supply of life saving drugs. We have significantly expanded our capacity for COVID drugs and have also partnered with global pharma companies and government authorities to bring innovative treatment options to the country,'' he noted.

MSME Benefits: Give relief to MSMEs benefited under RBI's Restructuring Framework 1.0

Startups: Techstars Bangalore picks 9 startups for third cohort in India

IPO Airlines: Go Airlines files draft papers for Rs 3,600 cr IPO